Clinical efficacy and safety of Guipi decoction combined with escitalopram oxalate tablets in patients with depression.
Depressive disorder
Escitalopram oxalate tablets
Jiajian Guipi decoction
Sleep quality
Traditional Chinese medicine syndromes
Journal
World journal of clinical cases
ISSN: 2307-8960
Titre abrégé: World J Clin Cases
Pays: United States
ID NLM: 101618806
Informations de publication
Date de publication:
16 Oct 2023
16 Oct 2023
Historique:
received:
12
07
2023
revised:
05
08
2023
accepted:
18
09
2023
medline:
10
11
2023
pubmed:
10
11
2023
entrez:
10
11
2023
Statut:
ppublish
Résumé
Depression is a widespread mental health condition that requires effective treatment. In the treatment of depression, traditional Chinese medicine (TCM) offers obvious advantages, fewer adverse reactions, and a lower recurrence rate. To evaluate the clinical benefits of Guipi decoction combined with escitalopram oxalate tablets for individuals with depression. In total, 80 patients diagnosed as having depression were enrolled in the study and divided into either an experimental group or a control group. All of the patients were orally administered escitalopram oxalate tablets. Additionally, the experimental group received Jiajian Guipi decoction and reduced Governor vessel fumigation over 4 wk. TCM syndrome scores, Hamilton depression rating scale (HAM-D) scores, self-rating depression scale (SDS) scores, and Pittsburgh sleep quality index scores were measured for the two groups and compared before and after the treatment. The two groups were monitored for any adverse reactions. After 4 wk of treatment, both groups exhibited a significant reduction in TCM syndrome scores compared with their pre-treatment scores ( The combination of Guipi decoction and escitalopram oxalate tablets was found to be an effective and safe treatment for depression. This combination could reduce TCM syndrome scores, improve depressive symptoms, and enhance sleep quality.
Sections du résumé
BACKGROUND
BACKGROUND
Depression is a widespread mental health condition that requires effective treatment. In the treatment of depression, traditional Chinese medicine (TCM) offers obvious advantages, fewer adverse reactions, and a lower recurrence rate.
AIM
OBJECTIVE
To evaluate the clinical benefits of Guipi decoction combined with escitalopram oxalate tablets for individuals with depression.
METHODS
METHODS
In total, 80 patients diagnosed as having depression were enrolled in the study and divided into either an experimental group or a control group. All of the patients were orally administered escitalopram oxalate tablets. Additionally, the experimental group received Jiajian Guipi decoction and reduced Governor vessel fumigation over 4 wk. TCM syndrome scores, Hamilton depression rating scale (HAM-D) scores, self-rating depression scale (SDS) scores, and Pittsburgh sleep quality index scores were measured for the two groups and compared before and after the treatment. The two groups were monitored for any adverse reactions.
RESULTS
RESULTS
After 4 wk of treatment, both groups exhibited a significant reduction in TCM syndrome scores compared with their pre-treatment scores (
CONCLUSION
CONCLUSIONS
The combination of Guipi decoction and escitalopram oxalate tablets was found to be an effective and safe treatment for depression. This combination could reduce TCM syndrome scores, improve depressive symptoms, and enhance sleep quality.
Identifiants
pubmed: 37946779
doi: 10.12998/wjcc.v11.i29.7017
pmc: PMC10631412
doi:
Types de publication
Journal Article
Langues
eng
Pagination
7017-7025Informations de copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: All authors declare that there are no conflicts of interest to disclose.
Références
Am Fam Physician. 2016 Dec 1;94(11):884-889
pubmed: 27929271
Curr Pharm Des. 2022;28(34):2771-2784
pubmed: 35619255
Biosci Rep. 2021 Feb 26;41(2):
pubmed: 33409535
Complement Ther Med. 2014 Aug;22(4):826-33
pubmed: 25146086
Psychoneuroendocrinology. 2021 Nov;133:105390
pubmed: 34425359
Prax Kinderpsychol Kinderpsychiatr. 2014;63(7):562-76
pubmed: 25478714
J Ethnopharmacol. 2016 Jul 21;188:234-58
pubmed: 27154405
Medicine (Baltimore). 2021 Oct 29;100(43):e27608
pubmed: 34713840
J Epidemiol Community Health. 2022 Apr;76(4):335-340
pubmed: 34625519
Comput Intell Neurosci. 2022 Oct 11;2022:1081713
pubmed: 36268156
Med Sci Monit. 2014 Sep 06;20:1583-9
pubmed: 25193932
Adolescence. 1991 Summer;26(102):361-74
pubmed: 1927668
Zhongguo Zhen Jiu. 2022 Feb 12;42(2):150-4
pubmed: 35152578
Int Clin Psychopharmacol. 2008 May;23(3):120-9
pubmed: 18408526
J Ethnopharmacol. 2021 May 10;271:113864
pubmed: 33485980
BMC Complement Altern Med. 2019 Nov 11;19(1):306
pubmed: 31711477
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2022 Aug 1;51(4):480-490
pubmed: 37202104
Sleep. 2011 Jun 01;34(6):807-15
pubmed: 21629370
J Head Trauma Rehabil. 2012 Mar-Apr;27(2):135-42
pubmed: 21386714
Behav Sleep Med. 2022 Sep-Oct;20(5):638-648
pubmed: 34511016
Ann Intern Med. 2007 Mar 6;146(5):317-25
pubmed: 17339617
Gen Hosp Psychiatry. 2020 Sep - Oct;66:70-80
pubmed: 32717644
Br Med Bull. 2015 Jun;114(1):169-79
pubmed: 25957394